p53 autoantibodies as tumor marker in head and neck squamous cell cancer.
p53 autoantibodies (AAB) are a new serological parameter with unknown potential in patients with malignancies. The reason why and the mechanism by which they develop is still unclear. So far, only in a limited number of studies has the usefulness of p53 AAB in the follow-up of cancer patients been shown. In this study 32 patients with head and neck cancer, seropositive for p53 AAB in their serum detected with an ELISA, were followed-up for at least 42 months. In 9 out of 32 p53 seropositive AAB head and neck cancer patients a correlation with the clinical course of the disease was seen. The remaining 23 of the p53 AAB-positive patients did not demonstrate any significant AAB titer changes during the follow-up and no significant correlation with the clinical course was observed. In conclusion, the clinical value of p53 AAB as a tumor marker for patients with head and neck cancer seems to be limited.
Gottschlich
Stefan
S
Department of Otorhinolaryngology, Head and Neck Surgery, University Clinic Kiel, Arnold-Heller-Str. 14, 24105 Kiel, Germany. gottschlich@hno.uni-kiel.de
Hoffmann
Markus
M
Maass
Jan D
JD
Görörgh
Tibor
T
Buhmann
Volker
V
Hoffmann-Fazel
Asita
A
Rudert
Heinrich
H
Maune
Steffen
S
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000175:diagnosis / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000473:pathology; D006801:Humans; D008875:Middle Aged; D015203:Reproducibility of Results; D016159:Tumor Suppressor Protein p53 / Q000097:blood*
D014408:Biomarkers, Tumor; D016159:Tumor Suppressor Protein p53